Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72022-07-014OAAI
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidinePHARMACEUTICALSIF4.82021-07-303OAAI
The therapeutic potential of 5-Azacitidine plus various BH3 mimetics in melanomaCANCER RESEARCHIF16.62020-08-150PRE
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsCELL DEATH & DISEASEIF9.62020-06-0852OAAI
未登录.png){kind=icon}
未登录
